A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

LUND, SE / ACCESS Newswire / April 29, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

The US regulator has cleared Lymphir (denileukin diftitox) for the treatment of relapsed or refractory cutaneous T-cell lymphoma ... by debilitating skin lesions and severe itching.

Hodgkin lymphoma and other CD30+ lymphomas have posed a major challenge to the medical community, especially in relapsed or refractory cases where conventional treatments have so far shown limited ...

CTCL is a rare and aggressive form of non-Hodgkin's lymphoma that originates in T-lymphocytes residing in ... It typically manifests with persistent skin lesions, itching, and potential systemic ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...